Recent Updates
Recently added Catalysts
PLSE Positive Sentiment

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pulse Biosciences reported significant business updates and financial results for Q3 2026. The company completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule. This achievement marks a notable milestone in their ongoing development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Completed enrollment in pivotal IDE study ahead of schedule.
  • Achieved major milestones since the second quarter.
  • Utilizing innovative Nanosecond Pulsed Field Ablation technology.

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the third quarter ended September 30, 2026. “Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan,” said

Frequently Asked Questions

What technology does Pulse Biosciences use?

Pulse Biosciences leverages Nanosecond Pulsed Field Ablation technology.

When did Pulse Biosciences complete IDE study enrollment?

Enrollment was completed in just six months.

How does the enrollment timeline compare to the plan?

Enrollment was completed three months ahead of plan.

What were the financial results for Q3 2026?

The article did not provide specific financial figures.

ShareAdd on Google
Tags: PLSE Pulse Biosciences financial results Q3 2026 IDE study
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$189M liquidity · $5M/mo burn
~37 mo
Minimal dilution risk